Hans‐Joachim Lück

4.9k total citations · 1 hit paper
67 papers, 2.9k citations indexed

About

Hans‐Joachim Lück is a scholar working on Oncology, Cancer Research and Reproductive Medicine. According to data from OpenAlex, Hans‐Joachim Lück has authored 67 papers receiving a total of 2.9k indexed citations (citations by other indexed papers that have themselves been cited), including 48 papers in Oncology, 24 papers in Cancer Research and 14 papers in Reproductive Medicine. Recurrent topics in Hans‐Joachim Lück's work include Cancer Treatment and Pharmacology (31 papers), HER2/EGFR in Cancer Research (25 papers) and Breast Cancer Treatment Studies (22 papers). Hans‐Joachim Lück is often cited by papers focused on Cancer Treatment and Pharmacology (31 papers), HER2/EGFR in Cancer Research (25 papers) and Breast Cancer Treatment Studies (22 papers). Hans‐Joachim Lück collaborates with scholars based in Germany, Switzerland and United States. Hans‐Joachim Lück's co-authors include Andreas du Bois, Christian Jackisch, Gϋnter von Minckwitz, Nadia Harbeck, Walther Kuhn, S. Olbricht, Jacobus Pfisterer, Uwe Wagner, Michael Untch and Rainer Kimmig and has published in prestigious journals such as Journal of Clinical Oncology, JNCI Journal of the National Cancer Institute and Cancer Research.

In The Last Decade

Hans‐Joachim Lück

66 papers receiving 2.8k citations

Hit Papers

Gemcitabine Plus Carboplatin Compared With Carboplatin in... 2006 2026 2012 2019 2006 100 200 300 400 500
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Gemcitabine Plus Carboplatin Compared With Carboplatin in Patients With Platinum-Sensitive Recurrent Ovarian Cancer: An Intergroup Trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG
    2006 540 citations Jacobus Pfisterer, Andreas du Bois et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Hans‐Joachim Lück Germany 28 1.9k 721 704 572 402 67 2.9k
B. Ojeda Spain 26 1.9k 1.0× 1.1k 1.5× 255 0.4× 388 0.7× 214 0.5× 57 2.8k
Deolinda Pereira Portugal 26 1.3k 0.7× 514 0.7× 1.3k 1.8× 323 0.6× 424 1.1× 86 2.8k
C. J. Rodenburg Netherlands 23 1.9k 1.0× 368 0.5× 328 0.5× 781 1.4× 466 1.2× 37 2.8k
D. Fennelly Ireland 25 1.8k 0.9× 377 0.5× 265 0.4× 564 1.0× 878 2.2× 85 2.6k
Anne Floquet France 30 1.3k 0.7× 521 0.7× 1.2k 1.8× 758 1.3× 665 1.7× 170 3.3k
Malgorzata Tuxen Denmark 18 687 0.4× 318 0.4× 947 1.3× 282 0.5× 486 1.2× 33 1.8k
Mayu Yunokawa Japan 25 1.1k 0.6× 373 0.5× 256 0.4× 482 0.8× 194 0.5× 140 2.1k
H. Curé France 22 1.2k 0.6× 742 1.0× 256 0.4× 327 0.6× 367 0.9× 82 2.0k
Edgar Petru Austria 33 1.5k 0.8× 897 1.2× 1.5k 2.1× 898 1.6× 749 1.9× 222 3.9k
Philippe Follana France 20 1.1k 0.6× 248 0.3× 1.3k 1.8× 523 0.9× 649 1.6× 83 2.3k

Countries citing papers authored by Hans‐Joachim Lück

Since Specialization
Citations

This map shows the geographic impact of Hans‐Joachim Lück's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hans‐Joachim Lück with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hans‐Joachim Lück more than expected).

Fields of papers citing papers by Hans‐Joachim Lück

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hans‐Joachim Lück. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hans‐Joachim Lück. The network helps show where Hans‐Joachim Lück may publish in the future.

Co-authorship network of co-authors of Hans‐Joachim Lück

This figure shows the co-authorship network connecting the top 25 collaborators of Hans‐Joachim Lück. A scholar is included among the top collaborators of Hans‐Joachim Lück based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hans‐Joachim Lück. Hans‐Joachim Lück is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Leman, Raphaël, Étienne Muller, Nicolas Goardon, et al.. (2022). 2022-RA-935-ESGO Development of an academic genomic instability score for ovarian cancers. International Journal of Gynecological Cancer. 32. A280–A280. 1 indexed citations
2.
Bronger, Holger, Silvia Egert, Peter A. Fasching, et al.. (2021). Abstract OT-26-01: ABEMACARE: Abemaciclib in combination with endocrine therapy as first line therapy in metastatic breast cancer patients with symptomatic visceral metastases or high tumor burden. Cancer Research. 81(4_Supplement). OT–26. 1 indexed citations
3.
Canzler, Ulrich, Hans‐Joachim Lück, Petra Neuser, et al.. (2020). Prognostic role of thrombocytosis in recurrent ovarian cancer: a pooled analysis of the AGO Study Group. Archives of Gynecology and Obstetrics. 301(5). 1267–1274. 6 indexed citations
4.
Gebauer, Gerhard, P. Hirnle, Wolfgang Janni, et al.. (2012). Influence of zoledronic acid on disseminated tumor cells in primary breast cancer patients. Annals of Oncology. 23(9). 2271–2277. 63 indexed citations
5.
Schippert, Cordula, Mathias Warm, Jens‐Uwe Blohmer, Andreas du Bois, & Hans‐Joachim Lück. (2012). Mitomycin C in Combination with Vinorelbine in Anthracycline- and/or Taxane-Pretreated Patients with Metastatic Breast Cancer. Onkologie. 35(9). 2–2. 1 indexed citations
6.
Minckwitz, Gϋnter von, Kathrin Schwedler, Marcus Schmidt, et al.. (2011). Trastuzumab beyond progression: Overall survival analysis of the GBG 26/BIG 3-05 phase III study in HER2-positive breast cancer. European Journal of Cancer. 47(15). 2273–2281. 141 indexed citations
7.
8.
Huober, Jens, W. Fett, Arnd Nusch, et al.. (2010). A multicentric observational trial of pegylated liposomal doxorubicin for metastatic breast cancer. BMC Cancer. 10(1). 2–2. 40 indexed citations
9.
Solomayer, Erich‐Franz, Gerhard Gebauer, P. Hirnle, et al.. (2009). Influence of zoledronic acid on disseminated tumor cells (DTC) in primary breast cancer patients.. Cancer Research. 69(2_Supplement). 2048–2048. 55 indexed citations
10.
Burzykowski, Tomasz, Marc Buyse, Martine Piccart, et al.. (2008). Evaluation of Tumor Response, Disease Control, Progression-Free Survival, and Time to Progression As Potential Surrogate End Points in Metastatic Breast Cancer. Journal of Clinical Oncology. 26(12). 1987–1992. 268 indexed citations
11.
Piccart, Martine, Tomasz Burzykowski, Marc Buyse, et al.. (2008). Taxanes Alone or in Combination With Anthracyclines As First-Line Therapy of Patients With Metastatic Breast Cancer. Journal of Clinical Oncology. 26(12). 1980–1986. 164 indexed citations
12.
Kandel, M., et al.. (2007). BRCA1 Germline Mutation in a Woman with Metaplastic Squamous Cell Breast Cancer. Oncology Research and Treatment. 30(6). 316–318. 16 indexed citations
13.
Konecny, G., Hans‐Joachim Lück, Michael Untch, et al.. (2004). HER-2/neu Gene Amplification and Response to Paclitaxel in Patients With Metastatic Breast Cancer. JNCI Journal of the National Cancer Institute. 96(15). 1141–1151. 110 indexed citations
14.
Reichardt, Peter, Gϋnter von Minckwitz, Peter Thuss‐Patience, et al.. (2003). Multicenter phase II study of oral capecitabine (Xeloda“) in patients with metastatic breast cancer relapsing after treatment with a taxane-containing therapy. Annals of Oncology. 14(8). 1227–1233. 202 indexed citations
15.
16.
Sturm, Isrid, Timo Hillebrand, T. Benter, et al.. (2000). Impaired BAX protein expression in breast cancer: Mutational analysis of the BAX and thep53 gene. International Journal of Cancer. 87(4). 517–521. 45 indexed citations
17.
Bois, Andreas du, Hans‐Joachim Lück, K. Buser, et al.. (1997). Extended phase II study of paclitaxel as a 3-h infusion in patients with ovarian cancer previously treated with platinum. European Journal of Cancer. 33(3). 379–384. 19 indexed citations
18.
19.
Lück, Hans‐Joachim, Christoph Thomssen, Andreas duBois, et al.. (1996). Interim Analysis of a Phase II study of epirubicin and paclitaxel as first-line therapy in patients with metastatic breast cancer.. PubMed. 23(1 Suppl 1). 33–6. 21 indexed citations
20.
Behrens, Otto K., Klaus Goeschen, Hans‐Joachim Lück, & Anna‐Riitta Fuchs. (1993). Effects of lumbar epidural analgesia on prostaglandin F2α release and oxytocin secretion during labor. Prostaglandins. 45(3). 285–296. 23 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by B. Ojeda Breakdown of academic impact, for papers by Deolinda Pereira Breakdown of academic impact, for papers by C. J. Rodenburg Breakdown of academic impact, for papers by D. Fennelly Breakdown of academic impact, for papers by Anne Floquet Breakdown of academic impact, for papers by Malgorzata Tuxen Breakdown of academic impact, for papers by Mayu Yunokawa Breakdown of academic impact, for papers by H. Curé Breakdown of academic impact, for papers by Edgar Petru Breakdown of academic impact, for papers by Philippe Follana
Rankless by CCL
2026